BioSpace News Archive

A novel study published in AACC’s Clinical Chemistry journal shows that a machine learning-based test detects emerging synthetic cannabinoids with greater ease than standard methods.

OSF Ventures joins six other investors in a Series A, $12.5 million funding round for a wireless, wearable EEG (brain wave monitor) to detect seizures, even those that are non-convulsive with no obvious signs.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced fourth quarter and full year 2021 financial results and provided an operational update.

CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, today welcomes the regulatory clearance of the Rika Plasma Donation System developed by Terumo Blood and Cell Technologies, a medical technology company based in Lakewood, Colorado.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its fourth quarter and full year 2021 financial results on Thursday, March 17, 2022.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2021 financial results.

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the year ended December 31, 2021, announced plans to conduct interim analyses of its OraGrowtH210 and OraGrowtH212 Trials, and provided an update on clinical activities and financial guidance for 2022.

via NewMediaWire – Neovasc Inc. reported financial results for the fourth quarter and year ended December 31, 2021.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today its financial results for the fourth quarter and full year 2021 and provided a corporate update.

Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that its Chief Executive Officer, Dr. Roger Crystal, will participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 - March 17.